August 13, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Unaudited Financial Results for the quarter ended June 30, 2026

The Board of Directors of the Company at their Meeting held on August 13, 2026, has inter alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2026.

Please find attached the Press Release regarding the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Prachi Suhas Sathe

Digitally signed by Prachi Suhas Sathe
Date: 2026.08.13 23:18:05 +05'30'

Prachi Sathe
Company Secretary & Compliance Officer

SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution

Supriya Lifescience Reports 31% YoY Revenue Growth in Q1 FY27

Mumbai, 13th August 2026: The unaudited financial statements for Q1FY27 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.

Key Consolidated Financial Highlights:

Particulars	Q1 FY27	Q1 FY26
Revenues (in Rs Cr)	189.75	145.07
EBITDA (in Rs Cr)	47.46	51.70
EBITDA Margin	25.0%	35.6%
PAT (in RsCr)	24.04	34.79
PAT Margin	12.7%	24.0%
Quarterly EPS (in Rs)	2.99	4.32

Key Highlights for Q1 FY27:

In Q1 FY27, Supriya Lifescience Ltd. witnessed a 30.8 % year-over-year growth in Revenue to Rs 189.75 crore compared to Rs 145.07 crore in Q1 FY26.

EBITDA for Q1 FY27 stood at Rs 47.46 crore, with an EBITDA margin of 25.0%, as against Rs 51.70 crore in Q1 FY26 with a margin of 35.6%.

The Profit After Tax (PAT) for Q1 FY27 was Rs 24.04 crore, compared to Rs 34.79 crore in Q1 FY26. The PAT Margin stood at 12.7% in Q1 FY27 versus 24.0% in Q1 FY26.

The **Anesthetic segment continued to be the largest therapeutic contributor** in Q1 FY27, accounting for **48% of revenue**, compared to 53% in Q1 FY26. Vitamins contributed **17%** of revenue in Q1 FY27, compared to 11% in Q1 FY26.

Asia became the largest market in Q1 FY27, contributing 39% of revenue, compared to 32% in Q1 FY26; while Europe's contribution came at 35% in Q1 FY27. LATAM contributed 20%, while North America and other markets contributed 3% each.

Export contribution stood at 81% of Q1 FY27 revenue, reflecting the Company's continued focus on global markets and diversified geographic presence.

During the quarter, the Company continued to build momentum across its product portfolio. The **Cardiovascular product launched in Q3 FY26** began contributing revenue in Q4 FY26, with momentum strengthening for future scale-up. The **ADHD product** witnessed strong demand from LATAM and Europe and is now scaling up. The **Liquid Anesthetic product** has been commercialised, with steady monthly supplies underway.

The Company is also advancing its **FY27 product pipeline**, with plans for approximately **two launches each in Anesthetic and ADHD**, aimed at deepening the product pipeline and supporting future growth.

Capacity utilisation stood at 70% in Q1 FY27, compared to 74% in FY26 and 70% in FY25. The Company continues to expand its manufacturing footprint, with a total reactor capacity of **932 KLPD** across its manufacturing blocks.

The **Ambernath facility** has commissioned its finished dosage manufacturing capabilities, with tablets, capsules, liquids, nasal, inhalation and injections among the dosage forms covered. Validation and registration batches are underway for dossier submissions.

The Company continues to strengthen its R&D capabilities, with **68+ scientists** focused primarily on API and formulation process development. The Company has also started two R&D centres at Ambernath and Lote, while continuing efforts to add **3–4 products annually**.

Dr. Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience Ltd., *commenting on the results, said, "Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth."*

……………………………………………………………………………………………………

looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our state-of-the-art facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities USFDA, EDQM, WHO, PMDA, KFDA and ANVISA are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For more details, contact:

Abhishek Chawande: Abhishek.Chawande@dentsu.com | 9664516774

Sanjukta Ghadge: Sanjukta.ghadge@dentsu.com | 98926 89895